Immix Biopharma Receives FDA Breakthrough Therapy Designation for NXC-201 for AL Amyloidosis
Thursday, January 29, 2026
Immix Biopharma has announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to NXC-201 for the treatment of relapsed or refractory AL amyloidosis.
AL amyloidosis is a serious condition in which abnormal immune cells produce toxic light chains. These proteins accumulate in vital organs such as the heart, kidneys and liver, leading to progressive organ damage and, in severe cases, death.
NXC-201 is a BCMA-targeted CAR-T cell therapy designed with a steric optimisation approach to reduce non-specific immune activation. The therapy aims to eliminate the cells responsible for producing toxic light chains. In addition to Breakthrough Therapy Designation, NXC-201 has also received Regenerative Medicine Advanced Therapy and Orphan Drug Designations from the FDA, as well as Orphan Drug Designation in the European Union.
The FDA’s Breakthrough Therapy programme is intended to speed up the development and review of medicines for serious conditions when early clinical data suggest meaningful improvement over existing treatment options.
The designation is supported by interim Phase 2 clinical data from the NEXICART-2 trial. These results were presented during an oral session at the American Society of Hematology annual meeting held in Orlando in December 2025.
NXC-201 is currently the only therapy in active development for relapsed or refractory AL amyloidosis to receive this designation. At present, there are no approved treatment options for patients with this advanced form of the disease.
Immix Biopharma is continuing patient enrolment in the NEXICART-2 study, with plans to progress towards a Biologics License Application submission within the year.
Source: globenewswire.com
